Deep智耀 Secures Another $40M Funding
💡Serial $150M funding in 3mo signals AI deep tech breakout
⚡ 30-Second TL;DR
What Changed
Raised $40M from returning investors including DCP, New Capital.
Why It Matters
Rapid serial funding underscores investor bets on Deep智耀's growth, potentially fueling AI infrastructure or vision tech scaling amid hot sector demand.
What To Do Next
Track Deep智耀's investor updates for potential AI tool or API partnership opportunities.
Key Points
- •Raised $40M from returning investors including DCP, New Capital.
- •Follows $60M round in Feb 2026 and $50M D-round in Dec 2025.
- •Total $150M secured in three months, with Index Capital as advisor.
- •Signals strong momentum in deep tech/AI sector.
🧠 Deep Insight
Background and context from public sources — not the original article. 5 sources cited.
🔑 Enhanced Key Takeaways
- •Deep Intelligent Pharma (DIP, 深度智耀) specializes in an end-to-end AI-driven drug R&D platform that integrates artificial intelligence and blockchain technologies to accelerate new drug development from lab to clinical trials.[1]
- •The platform focuses on enhancing efficiency in drug discovery, application, and delivery processes across laboratory and clinical stages.[1][3]
🔮 Future ImplicationsAI analysis grounded in cited sources
⏳ Timeline
📎 Sources (5)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 36氪 ↗
This is a summary, not the original. Read the source, or get the weekly briefing.
Weekly AI briefing
One email a week. Unsubscribe anytime.